Science and Developments 2023
We are proud to have supported a wide range of research throughout 2023, spanning from fundamental scientific exploration to groundbreaking pharmaceutical initiatives!?
At Sciomics, our passion for advanced protein profiling drives the future of Precision Medicine. Our cutting-edge services empower scientists worldwide to unravel the complexities of diseases, uncover drug mode-of-action mechanisms and identify promising protein biomarker candidates.
We would like to thank Abbvie and Singleron Biotechnologies for the wonderful and very productive collaboration this year. This has allowed us to gain new insights into biomarkers for neurodegenerative diseases, which were presented in two posters at the prestigious AAIC conference in Amsterdam! We would also like to thank Roche for the great collaboration on the dengue virus, which identified important predictive biomarkers for dengue deterioration. The results were presented at the 6th Asia Dengue Summit. Our very fruitful collaboration with Kiffik Biomedical Inc. has yielded important proof-of-concept data for establishing interstitial fluid as a fantastic source for new biomarkers and for disease characterization. Furthermore, we are working with Neuro-Sys to establish next generation animal models for neurodegenerative diseases.
Many of our partners' projects were completed this year, supporting their basic research activities and preclinical development pipelines. For example, we supported two pancreatic cancer projects, both highly published in Nature and Nature Communications. Another study?published?this year focused on proteomic analysis of blood samples with?different acute and convalsecent infections, comparing different pathogens and identifying differences and similarities in the immune response depending on the type of infection.
The Eurostars project 3D-Screen to better understand treatment response in immuno-oncology has also been successfully completed. We are now part of two new research projects launched this year: The Nanodiag excellence initiative for new, innovative diagnostics and the EV-Surf project for better prostate cancer diagnostics based on extracellular vesicles.?
We are pleased to have participated in many important national and international conferences, including Bio Europe Spring, BioEurope, BIO International, BioJapan, the NLSDs, the AAIC, the ADLM Annual Meeting and RexPo23 drug repurposing conference, to name but a few. We have made new connections with scientists around the world, had in-depth discussions about the future of medicine and started new collaborations.
During 2023 we made significant progress in our internal biomarker pipeline for the prediction of severe COVID-19 and perioperative acute kidney injury (AKI) for individualized, risk-adjusted patient management. This year we published our first independent biomarker research on predictive COVID-19 biomarkers in Nature Communications Medicine. Based on this research, we have also filed two international biomarker patent applications. We look forward to expanding this research and translating our findings into clinical application. In this context, we would like to thank BioRN for their great cooperation and support in the market research for AKI USA. Access to their databases and expert interviews provided critical information on market potential and important aspects for the further development of our AKI project.
We already know that 2024 will be filled with even more interesting projects with customers and collaborators. We will start the biomarker study within the BRACE project, start the biomarker studies for the two REPO4EU projects on stroke diagnosis and cardiac disease, and will complete establishing a drug response biomarker signature within the MCDS-Therapy consortium. We will also further develop our internal diagAKI pipeline to bring biomarker-based AKI prediction and diagnosis to patients.
Follow us to stay up to date on our research – and contact us if you have any questions or want to harness the power of proteome profiling for your project!
Whether you're in need of guidance, have questions, or require full-scale project support, our team is here to support your research:
领英推荐
Thank you for joining us on this exciting journey of proteomic discovery. We are happy to have you as a part of the Sciomics community! Together, we can reshape the future of healthcare.?
We wish you and your loved ones a Merry Christmas and a Happy New Year! Cheers to a new year filled with fruitful collaborations and advancements in science!
Your Sciomics Team
?
Increased monocyte activity identified in Alzheimer’s disease by in depth single-cell genomic and proteomic analysis https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/71084
Exploration of novel biomarkers for neurodegenerative diseases using ligand-binding assays https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/76362
Identification of biomarkers for prediction of dengue deterioration (link to programme book containing abstract of the study) https://www.asiadenguesummit.org/wp-content/uploads/6th-Asia-Dengue-Summit-Programme-Book.pdf
Tintelnot, J., Xu, Y., Lesker, T.R.?et al.?Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer.?Nature?615, 168–174 (2023). https://doi.org/10.1038/s41586-023-05728-y
Wiedmann, L., De Angelis Rigotti, F., Vaquero-Siguero, N.?et al.?HAPLN1 potentiates peritoneal metastasis in pancreatic cancer.?Nat Commun?14, 2353 (2023). https://doi.org/10.1038/s41467-023-38064-w
Sigdel, T.K., Sur, S., Boada, P.?et al.?Proteome Analysis for Inflammation Related to Acute and Convalescent Infection.?Inflammation?(2023). https://doi.org/10.1007/s10753-023-01913-3
Hufnagel, K., Fathi, A., Stroh, N.?et al.?Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Commun Med?3, 51 (2023). https://doi.org/10.1038/s43856-023-00283-z